首页> 美国卫生研究院文献>other >Evaluation of the Implementation of CDC’s Health Alert Related to the FDA LeadCare Recall From the State Health Department Perspective
【2h】

Evaluation of the Implementation of CDC’s Health Alert Related to the FDA LeadCare Recall From the State Health Department Perspective

机译:从国家卫生部的角度评估CDC与FDA LeadCare召回相关的健康警报的实施情况

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

On May 17, 2017, the Food and Drug Administration (FDA) issued a safety recall for the Magellan Diagnostics’ LeadCare Testing Systems due to the potential for inaccurately low blood lead test results when used with venous blood samples. The Centers for Disease Control and Prevention (CDC) announced a health alert with retesting recommendations because those with a blood lead level of concern may have been missed and not connected to the appropriate follow-up services. A qualitative evaluation of 9 state childhood lead poisoning prevention programs’ experiences is presented in this report. Interviewees reported using a variety of media and notification methods to inform key stakeholders about the recall and recommendations. Challenges experienced by programs in responding to retesting recommendations include incomplete and out-of-date lists of LeadCare users; missing or inaccurate information in their surveillance database; not having large laboratories and hospitals consider contacting persons for retesting to be within their purview; and having limited staff members to conduct emergency response activities. Two of the 9 states report subsequent challenges with their retesting rates. The retesting recommendations were generally viewed positively. The interviewees’ comments provide insight into steps CDC might take to better serve state and local lead programs. Programs’ experiences have led to a better understanding of the roles of their program when emergency events occur, their relationship with stakeholders as related to the blood lead testing and reporting process, and areas of improvement in surveillance databases. Public health agencies at all levels have important roles to play in preventing lead exposures and providing needed services when exposures occur. Programs may achieve long-term benefits by improving surveillance systems and having a better understanding of laboratory practices. CDC will continue to provide timely information and recommendations to state and local public health agencies to inform both routine and emergency response activities.
机译:2017年5月17日,美国食品药品监督管理局(FDA)对Magellan Diagnostics的LeadCare检测系统发布了安全召回通知,原因是与静脉血样本一起使用时,低铅检测结果可能不准确。疾病控制与预防中心(CDC)宣布了一项健康警报,并提出了重新测试的建议,因为那些血铅水平令人担忧的人可能已经错过了,并且没有与适当的随访服务联系在一起。该报告对9个州的儿童期铅中毒预防计划的经验进行了定性评估。受访者报告使用各种媒体和通知方法来向主要利益相关者告知召回和建议。程序在响应重新测试建议时遇到的挑战包括LeadCare用户列表的不完整和过时;他们的监视数据库中的信息缺失或不准确;没有大型实验室和医院考虑将人员联系以进行重新测试不在其权限范围内;有限的人员进行紧急响应活动。 9个州中有2个州报告其重测率面临后续挑战。对重新测试的建议普遍持积极态度。受访者的评论提供了CDC可能采取的步骤,以更好地服务于州和地方领导计划。程序的经验使人们可以更好地了解程序在发生紧急事件时的角色,与血铅测试和报告过程有关的与利益相关者的关系以及监控数据库的改进领域。各级公共卫生机构在预防铅暴露和在发生铅暴露时提供必要的服务方面都可以发挥重要作用。通过改进监视系统并更好地了解实验室操作,程序可以实现长期利益。疾病预防控制中心将继续向州和地方公共卫生机构提供及时的信息和建议,以为例行和紧急响应活动提供信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号